A monthly snapshot of FDA activity involving therapies for the prevention and treatment of neurologic diseases.

Results from the OCEANIC-STROKE trial show that the investigational Factor XIa inhibitor, asundexian, not only reduces the ...

A US study found that giving oseltamivir to ≥ 70% of nursing home residents within 48 hours of an outbreak cut ...

Upadacitinib is effective in inducing clinical response and remission and is generally well tolerated in patients with ...

The Alberta government has proposed a voucher program for patients who have waited longer than is recommended for surgery.

Researchers highlight that age, not ovarian reserve, drives fertility decline, thereby questioning the clinical value of ...

A blood test measuring levels of basophil activation markers identifies sesame seed allergy more accurately than skin prick ...

Dual-energy CT with virtual non-calcium reconstruction provides high specificity in detecting bone marrow oedema in ...

A new study integrates multiple genetic risk scores to better identify people at high risk for eight cardiovascular ...

The use of calcitonin gene-related peptide (CGRP) inhibitors to treat adults with migraine is linked to a 25% lower risk for ...

A comparative analysis identifies the top IL-23 inhibitors that were least likely to be associated with the development of ...

Plant-based protein consumption is associated with a lower risk for CVD, but its effects depend on food quality, processing, ...